Valuation dashboard for Fractyl Health, Inc. (GUTS) with P/E N/A, P/B -52.73, EV/EBITDA -1.19 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.56, GUTS has negative trailing earnings (P/E not meaningful) and an ROE of -16.26%. Market capitalisation stands at $89M.
Balance sheet quality for GUTS: current ratio of 4.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -52.73 |
| EV / EBITDA | -1.19 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.12 |
| vs Current Price | -78.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GUTS | Fractyl Health, Inc. | $89M | -16.3% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.56 |
| Market Cap | $89M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -1625.88% |
| Return on Invested Capital | -120.27% |
| Return on Assets | -128.88% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADVM · ALXO · ARTV · ATYR · BMEA · DTIL · MGX
Explore sector: Healthcare · Biotechnology
More sections of GUTS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks